Our law firm is currently handling lawsuits on behalf of individuals who have taken Onglyza and Kombiglyze XR to treat Type 2 diabetes. Lawsuits allege that Onglyza and Kombiglyze XR may lead to serious cardiac complications and even death.
Onglyza and Kombiglyze XR were approved by the U.S. Food and Drug Administration (FDA) to control high blood sugar in individuals with Type 2 diabetes. Saxagliptin, the active ingredient in Onglyza and Kombiglyze XR, regulates blood sugar and does not promote weight gain. It promotes insulin production in the pancreas and prevents the liver from producing excess glucose. Onglyza is one of the most popular drugs to treat Type 2 diabetes.
Hundreds of lawsuits have been filed against AstraZeneca alleging that Onglyza and Kombiglyze XR (saxaglipton plus metformin HCI extended release) may cause serious heart disease, including congestive heart failure. Lawsuits also claim that the manufacturer began selling the medications in 2009 and 2010 before finalizing a safety analysis as recommended by the FDA. In 2016, the FDA required the company to include additional warnings about cardiovascular complications.
Onglyza and Kombiglyze XR increase the risk of cardiovascular disease, namely congestive heart failure, heart attacks, and cardiac related death. Symptoms associated with Onglyza and Kombiglyze XR include shortness of breath, fatigue, irregular heartbeat, swelling, and chest pain.
If you or a loved one has been injured by Onglyza and Kombiglyze XR, you may recover compensation for any or all of the following:
The Lake Law Firm was founded by Edward J. Lake, Esq., a personal injury lawyer for over 25 years. Our dedicated team of attorneys is committed to seeking justice on behalf of those who have suffered injury or death due to the negligence of others. Our experienced attorneys handle many different types of pharmaceutical drugs, medical devices, and other defective products. The lawyers in our firm have helped collect millions of dollars for their clients. The Lake Law Firm will advocate for you and your rights. Please contact us for a free confidential case evaluation at (888) 525-3529 or submit an inquiry on this page.
AstraZeneca conducted a study of saxagliptin in 2013 that determined that the diabetes medication may cause serious cardiovascular side effects. Following the study, in 2016, the FDA issued a warning to patients taking Onglyza and Kombiglyze XR that they may be at increased risk of heart failure. This warning was based on a study that concluded that those who took medications containing saxagliptin were 25% more likely to experience heart failure than patients taking a placebo. The FDA required the manufacturers of Onglyza and Kombiglyze XR to place an additional warning on their labels to alert patients about the risk of heart failure. The elevated risk of heart failure was most evident in patients who had pre-existing heart conditions or kidney disease.
The Lake Law Firm
N/a
